Clinical pilot study: Efficacy of triple antibiotic therapy in Blastocystis positive irritable bowel syndrome patients

Gut Pathogens

Volumn 6, Issue 1, 2014, Pages

  Nagel, Robyn ^a,c   Bielefeldt Ohmann, Helle ^a   Traub, Rebecca ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Toowoomba Gastroenterology Clinic   (Australia)

Author keywords

Blastocystis; Irritable bowel syndrome; PCR; Therapy

Indexed keywords

EID: 84908307815     PISSN: None     EISSN: 17574749     Source Type: Journal    
DOI: 10.1186/s13099-014-0034-0     Document Type: Article

References (51)

1. New insights on classification, identification, and clinical relevance of Blastocystis spp. KS Tan, Clin Microbiol Rev 2008 21 4 639 665 10.1128/CMR.00022-08 18854485
2. Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population. DEM-FW Jimenez-Gonzalez, J Reues-Gordillo, M Ramirez-Mirnada, S Arroyo-Escalante, M Romero-Valdovinos, D Stark, V Souza-Saldivar, F Martinez-Hernandez, A Flisser, A Olivo-Diaz, P Maravilla, Parasitol Res 2012 110 3 1269 1275 10.1007/s00436-011-2626-7 21870243
3. Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara, Turkey. F Dogruman-Al, Z Simsek, K Boorom, E Ekici, M Sahin, C Tuncer, S Kustimur, A Altinbas, PLoS One 2010 5 11 15484 10.1371/journal.pone.0015484 21124983
4. Introduction. The Rome Foundation and Rome III. DA Drossman, Neurogastroenterol Motil 2007 19 10 783 786 10.1111/j.1365-2982.2007.01001.x 17883428
5. The economic impact of irritable bowel syndrome. JMFM Inadomi, D Bjorkman, Aliment Pharmacol Therapeut 2003 18 7 671 682 10.1046/j.1365-2036.2003.t01-1-01736.x
6. Post-infectious irritable bowel syndrome: Mechanistic insights into chronic disturbances following enteric infection. JKBA Beatty, AG Buret, World J Gastroenterol 2014 20 14 3976 3985 10.3748/wjg.v20.i14.3976 24744587
7. A role for the gut microbiota in IBS. S Collins, Nat Rev Gastroenterol Hepatol 2014 11 8 497 505 10.1038/nrgastro.2014.40 24751910
8. Review article: evidence for the role of gut microbiota in irritable bowel syndorme and its potential influence on therapeutic targets. H DuPont, Aliment Pharmacol Ther 2014 39 1033 1042 10.1111/apt.12728 24665829
9. Gastrointestinal microbiota in irritable bowel syndrome:present state and perspectives. A de Salonen, WM Vos, A Palva, Microbiology 2010 156 3205 3215 10.1099/mic.0.043257-0 20705664
10. Review article:associations between immune activation, intestinal permeability and the irritable bowel syndrome. JM Matricon, A Gelot, T Piche, M Dapoigny, E Muller, D Ardid, Aliment Pharmacol Ther 2012 36 1009 1031 10.1111/apt.12080 23066886
11. Proinflammatory cytokines disrupt epithelial barrier funciton by apoptosis-independent mechanisms. M LA Bruewer, T Kucharzik, CA Parkos, JL Madara, AM Hopkins, A Nusrat, J Immunol 2003 171 6164 6172 10.4049/jimmunol.171.11.6164 14634132
12. Bacterial proteases in IBD and IBS. NMK Steck, M Schermann, D Haller, Gut 2014 61 1610 1618 10.1136/gutjnl-2011-300775
13. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic luminal factor impairing colonic permeability and sensitivity. K Gecse, R Roka, L Ferrier, H Eutamene, C Cartier, A Ait-Belgnaoui, A Rosztoczy, F Izbeki, J Fioramonti, T Wittmann, L Bueno, Gut 2008 57 5 591 599 10.1136/gut.2007.140210 18194983
14. Blastocystis ratti contains cysteine proteases that mediate interleukin-8 response from human intestinal epithelial cells in an NF-kappaB-dependent manner. MK Puthia, J Lu, KS Tan, Eukaryot Cell 2008 7 3 435 443 10.1128/EC.00371-07 18156286
15. Blastocystis ratti Induces contact-independent apoptosis, F-actin rearrangement, and barrier function disruption in IEC-6 cells. MK Puthia, SWS Sio, J Lu, KSW Tan, Infect Immun 2006 74 7 4114 4123 10.1128/IAI.00328-06 16790785
16. Degradation of human secretory immunoglobulin A by Blastocystis. MK Puthia, A Vaithilingam, J Lu, KS Tan, Parasitol Res 2005 97 5 386 389 10.1007/s00436-005-1461-0 16151742
17. Blastocystis exhibits inter- and intra-subtype variation in cysteine protease activity. H Mirza, KS Tan, Parasitol Res 2009 104 2 355 361 10.1007/s00436-008-1203-1 18846388
18. Blastocystis legumain is localized on the cell surface, and specific inhibition of its activity implicates a pro-survival role for the enzyme. B Wu, J Yin, C Texier, M Roussel, KS Tan, J Biol Chem 2010 285 3 1790 1798 10.1074/jbc.M109.049064 19915007
19. Irritable bowel syndrome: is it associated with genotypes of Blastocystis hominis. J Yakoob, W Jafri, MA Beg, Z Abbas, S Naz, M Islam, R Khan, Parasitol Res 2010 106 5 1033 1038 10.1007/s00436-010-1761-x 20177906
20. Comparison of Sequencing (Barcode Region) and Sequence-Tagged-Site PCR for Blastocystis Sub-typing. CR Stensvold, J Clin Microbiol 2013 51 190 194 10.1128/JCM.02541-12 23115257
21. Eradication of Blastocystis carriage with antimicrobials: reality or delusion? CR Stensvold, HV Smith, R Nagel, KE Olsen, RJ Traub, J Clin Gastroenterol 2009 44 2 85 90 10.1097/MCG.0b013e3181bb86ba
22. Blastocystis subtypes in symptomatic and asymptomatic family members and pets and response to therapy. R Nagel, L Cuttell, CR Stensvold, PC Mills, H Bielefeldt-Ohmann, RJ Traub, Intern Med J 2012 42 11 1187 1195 10.1111/j.1445-5994.2011.02626.x 22032439
23. A medium for investigating the breakdown of pectin by bacteria. DR Jones, Nature 1946 158 4018 625 10.1038/158625b0 21065340
24. Predominance of subtype 3 among Blastocystis isolates from a major hospital in Singapore. KH Wong, GC Ng, RT Lin, H Yoshikawa, MB Taylor, KS Tan, Parasitol Res 2008 102 4 663 670 10.1007/s00436-007-0808-0 18064490
25. MEGA2:Molecular Evolutionary Genetics Analysis software. S Kumar, K Tamura, IB Jakobsen, M Nei, Bioinformatics 2001 17 12 1244 1245 10.1093/bioinformatics/17.12.1244 11751241
26. Treatment failure in patients with chronic Blastocystis infection. T Roberts, J Ellis, J Harkness, D Marriott, D Starl, J Med Microbiol 2014 63 252 257 10.1099/jmm.0.065508-0 24243286
27. Development of metronidazole-resistant lines of Blastocystis spp. TK LA Dunn, P Vanelle, T Juspin, MD Crozet, T Terme, P Upcroft, JA Upcroft, Parasitol Res 2012 111 441 450 10.1007/s00436-012-2860-7 22362365
28. A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype-dependent variations in drug susceptibilities. H Mirza, JDW Teo, J Upcroft, KSW Tan, Antimicrob Agents Chemother 2010 55 2 637 648 10.1128/AAC.00900-10 21098237
29. In vitro response of Blastocystis hominis to antiprotozoal drugs. CH Zierdt, JC Swan, J Hosseini, J Protozool 1983 30 2 332 334 10.1111/j.1550-7408.1983.tb02925.x 6631776
30. Blastocystis hominis: neutral red supravital staining and its application to in vitro drug sensitivity testing. AA Vdovenko, JE Williams, Parasitol Res 2000 86 7 573 581 10.1007/PL00008533 10935909
31. The in-vitro activity of drugs against Blastocystis hominis. LA Dunn, PF Boreham, J Antimicrob Chemother 1991 27 4 507 516 10.1093/jac/27.4.507 1856129
32. Pharmacokinetics and Pharmacodynamics of the Nitroimidazole Antimicrobials. KCFC Lamp, NE Klutman, MK Lacy, Clin Pharmacokinet 1999 36 5 353 373 10.2165/00003088-199936050-00004 10384859
33. Blastocystis: to treat or not to treat. CMJV Coyle, M Louis Weiss, B Herbert Tanowitz, Clin Prac 2012 54 105 107
34. Bioavailability of oral antibiotics in children with short bowel syndrome. GGJ Menardi, J Paediatr Surg 1984 19 1 84 86 10.1016/S0022-3468(84)80023-8
35. Paromomycin. RN dBM Davidson, K Ritmeijer, Trans R Soc Trop Med Hyg 2008 103 653 660 10.1016/j.trstmh.2008.09.008 18947845
36. Is paromomycin the drug of choice for eradication of Blastocystisin adults? JMN van Hellemond, R Koelewijn, PJ Wismans, PJ Genderen, J Infect Chemother 2013 19 545 548 10.1007/s10156-012-0496-2 23053509
37. A novel nonabsorbed rifamycin for gastrointestinal disorders. JA Adachi, DH Rifaximin, Clin Infect Dis 2006 2006 42 541 547 10.1086/499950
38. Rifaximin therapy for patients with irritable bowel syndrome wihout constipation. M Pimentel, A Lembo, W Chey, S Zakko, Y Ringel, J Yu, S Mareya, A Shaw, E Bortey, W Forbes, NEJM 2011 364 22 32 10.1056/NEJMoa1004409 21208106
39. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. M Amenta, ER Dalle Nogare, C Colomba, T Prestileo, F Di Lorenzo, S Fundaro, A Colomba, A Ferrieri, J Chemother 1999 11 5 391 395 10.1179/joc.1999.11.5.391 10632386
40. Stability studies on diloxanide furoate: effect of pH, temperature, gastric and intestinal fluids. EA Gadkariem, F Belal, MA Abounassif, HA El-Obeid, KE Ibrahim, Il Farmaco 2004 59 323 329 10.1016/j.farmac.2003.11.015 15081350
41. Cross-sectional surveys and subtype classification of human Blastocystis isolates from four epidemiological settings in China. LH Li, XP Zhang, S Lv, L Zhang, H Yoshikawa, Z Wu, P Steinmann, J Utzinger, X Tong, S Chen, X Zhou, Parasitol Res 2007 102 1 83 90 10.1007/s00436-007-0727-0 17912552
42. Development and evaluation of a real-time PCR assay for detection and quantification of blastocystis parasites in human stool samples: prospective study of patients with hematological malignancies. P Poirier, I Wawrzyniak, A Albert, H El Alaoui, F Delbac, V Livrelli, J Clin Microbiol 2011 49 3 975 983 10.1128/JCM.01392-10 21177897
43. Clinical significance and frequency of Blastocystis hominis in Turkish patients with hematological malignancy. Y Tasova, B Sahin, S Koltas, S Paydas, Acta Med Okayama 2000 54 3 133 136 10925738
44. Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis. A Olivo-Diaz, M Romero-Valdovinos, A Gudino-Ramirez, J Reyes-Gordillo, D Jimenez-Gonzalez, M Ramirez-Miranda, W Martinez-Flores, F Martinez-Hernandez, A Flisser, P Maravilla, Parasitol Res 2012 111 487 491 10.1007/s00436-012-2830-0 22287022
45. IgA deficiency and autoimmunity. K Singh, C Chang, M Gershwin, Autoimmun Rev 2014 13 163 177 10.1016/j.autrev.2013.10.005 24157629
46. Serum immunoglobulin levels in healthy children and adults. JW Stoop, B Zegers, P Sander, R Ballieux, Clin exp Immunol 1969 4 101 112 4182354
47. In vivo encystation of Blastocystis hominis. K Suresh, GD Venilla, TC Tan, M Rohela, Parasitol Res 2009 104 303 307 10.1007/s00436-009-1340-1
48. Detecting Blastocystis using parasitologic and DNA-based methods: a comparative study. CR Stensvold, M Arendrup, C Jespersgaard, K Molbak, H Nielsen, Diag Microbiol Inf Dis 2007 59 303 307 10.1016/j.diagmicrobio.2007.06.003
49. Significantly increased IgG2 subclass antibody levels in patients with irritable Bowel Syndrome. R Hussain, W Jaferi, A Zuberi, R Baqai, N Abrar, A Ahmed, V Zaman, Am J Trop Med Hyg 1997 56 301 306 9129532
50. The potential us of 29 kDa protein as a marker of pathogenicity and diagnosis of symptomatic infections with Blastocystis hominis. M Abou Gamra, H Elwakil, H El Deeb, K Khalifa, H Abd Elhafiz, Parasitol Res 2011 108 1139 1146 10.1007/s00436-010-2156-8 21136081
51. Treatment of giardiasis. T Gardner, D Hill, Clin Microbiol Rev 2001 14 114 128 10.1128/CMR.14.1.114-128.2001 11148005